List of Probuphine drug patents

Probuphine is owned by Titan Pharms.

Probuphine contains Buprenorphine Hydrochloride.

Probuphine has a total of 1 drug patent out of which 0 drug patents have expired.

Probuphine was authorised for market use on 26 May, 2016.

Probuphine is available in implant;implantation dosage forms.

Probuphine can be used as for opioid dependence.

The generics of Probuphine are possible to be released after 25 April, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7736665 TITAN PHARMS Implantable polymeric device for sustained release of buprenorphine
Apr, 2024

(1 year, 2 months from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient

Market Authorisation Date: 26 May, 2016

Treatment: For opioid dependence

Dosage: IMPLANT;IMPLANTATION

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in